NCT01928329View on ClinicalTrials.gov

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

August 31, 2019

Conditions
Type I Diabetes
Interventions
DRUG

Exenatide (Bydureon®)

DRUG

Placebo

Trial Locations (8)

13210

SUNY Upstate Medical University, Syracuse

33136

University of Miami, Miami

48105

University of Michigan, Ann Arbor

Unknown

University of California, San Francisco, San Francisco

Barbara Davis Center, Aurora

Yale University, New Haven

University of Chicago, Chicago

02215

Joslin Diabetes Center, Boston

All Listed Sponsors
lead

Yale University

OTHER

NCT01928329 - A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes | Biotech Hunter | Biotech Hunter